New Zealand markets closed
  • NZX 50

    12,348.00
    -149.10 (-1.19%)
     
  • NZD/USD

    0.6713
    -0.0047 (-0.70%)
     
  • NZD/EUR

    0.5911
    -0.0058 (-0.97%)
     
  • ALL ORDS

    7,490.10
    -178.80 (-2.33%)
     
  • ASX 200

    7,175.80
    -166.60 (-2.27%)
     
  • OIL

    84.83
    -0.72 (-0.84%)
     
  • GOLD

    1,836.10
    -6.50 (-0.35%)
     
  • NASDAQ

    14,438.40
    -408.06 (-2.75%)
     
  • FTSE

    7,494.13
    -90.88 (-1.20%)
     
  • Dow Jones

    34,265.37
    -450.02 (-1.30%)
     
  • DAX

    15,603.88
    -308.45 (-1.94%)
     
  • Hang Seng

    24,965.55
    +13.20 (+0.05%)
     
  • NIKKEI 225

    27,522.26
    -250.67 (-0.90%)
     
  • NZD/JPY

    76.2790
    -0.7870 (-1.02%)
     

Charles River Laboratories to Participate in Upcoming Investor Conferences

·1-min read

WILMINGTON, Mass., November 16, 2021--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at two upcoming investor conferences, including:

  • Jefferies London Healthcare Conference on Thursday, November 18th, with a pre-recording of the presentation available starting at 8:00 a.m. GMT (3:00 a.m. ET); and

  • Evercore ISI 4th Annual HealthCONx Conference on Wednesday, December 1st, at 9:40 a.m. ET.

Management will present an overview of Charles River’s strategic focus and business developments.

A webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after each event and will remain available for approximately two weeks.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005084/en/

Contacts

Investor Relations Contact:
Todd Spencer
Corporate Vice President, Investor Relations
781.222.6455
todd.spencer@crl.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting